Price Chart

Headline
Wire
Time (ET)
DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/18/2022* 10:00 EST Earnings Call Q2 2022 -- -- --
02/18/2022* -- Results Q2 2022 -- -- --
08/18/2021 -- Results Q4 2021 -- -- --
02/18/2021 -- Results Q2 2021 -- -- --
02/18/2021 18:00 EST Earnings Call Q2 2021 -- -- --
08/19/2020 -- Results Q4 2020 -- -- --
02/12/2020 -- Results Q2 2020 -- -- --
08/14/2019 -- Results Q4 2019 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/18/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade
 
4.00
2.00
1.00
 
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
No data available
Last Report Date 08/18/2021
Beat/Miss Upgrade
Return Since -11.66%
Last FQE 06/30/2021
Next FQE 09/30/2021

Profile

Edit
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
URL https://www.csl.com
Investor Relations URL https://investors.csl.com/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release Feb. 18, 2022
Last Earnings Release Aug. 18, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Sep. 01, 2021

Dividends

Dividend Per Share (TTM) 1.055
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 1.044
Yield to Sector 0.8685
Yield to Industry 2.178
Last Dividend Amt. 0.59
Dividend Frequency Semi-Annually
Last Ex-Dividend Date Sep. 01, 2021
Yield (TTM) 1.19%
Forward Yield 1.27%
Payout Ratio 40.34%
Cash Payout Ratio --
Consistent Payer (5Y) Yes
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
10.29%
-3.66%
54.17%
18.71%
52.13%
14.37%
-2.96%
-12.04%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.54%
-55.85%
-62.48%
91.41%
-58.97%
-39.06%
71.79%
-46.27%
10.46%
0.48%
-29.90%
-45.74%
-23.58%
78.60%
99.08%
-2.55%
-25.77%
70.12%
-38.42%
-32.91%
17.20%
-2.72%
75.42%
4.46%
-23.17%
--
--
255.6%
-69.62%
270.4%
-22.12%
-32.72%
-5.90%
As of January 26, 2022.

Profile

Edit
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
URL https://www.csl.com
Investor Relations URL https://investors.csl.com/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release Feb. 18, 2022
Last Earnings Release Aug. 18, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Sep. 01, 2021

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
EVF171 9.526M USD 4.53%
LIFE.TO 9.526M USD 4.53%
F00001CIVX 428860.0 USD 4.29%
F00001D0MM 388003.0 USD 3.88%
FVHIHX 369990.0 USD 3.70%
F0000173CB 366150.0 USD 3.66%
FUVVKX 361516.0 USD 3.62%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits CSLLY Tweets